BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33520368)

  • 1. Tumor-intrinsic and -extrinsic (immune) gene signatures robustly predict overall survival and treatment response in high grade serous ovarian cancer patients.
    Mysona DP; Tran L; Bai S; Dos Santos B; Ghamande S; Chan J; She JX
    Am J Cancer Res; 2021; 11(1):181-199. PubMed ID: 33520368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    Hillman RT; Chisholm GB; Lu KH; Futreal PA
    J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer.
    Zhao Y; Yang SM; Jin YL; Xiong GW; Wang P; Snijders AM; Mao JH; Zhang XW; Hang B
    J Oncol; 2019; 2019():3614207. PubMed ID: 31885574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
    An Y; Bi F; You Y; Liu X; Yang Q
    J Cancer; 2018; 9(21):4058-4071. PubMed ID: 30410611
    [No Abstract]   [Full Text] [Related]  

  • 7. RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
    Jones WD; Michener CM; Biscotti C; Braicu I; Sehouli J; Ganapathi MK; Ganapathi RN
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32156016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.
    Dai D; Li Q; Zhou P; Huang J; Zhuang H; Wu H; Chen B
    Front Cell Dev Biol; 2022; 10():874588. PubMed ID: 35769257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response.
    Mairinger F; Bankfalvi A; Schmid KW; Mairinger E; Mach P; Walter RF; Borchert S; Kasimir-Bauer S; Kimmig R; Buderath P
    Cancer Manag Res; 2019; 11():9571-9583. PubMed ID: 31814759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
    Tran LKH; Tran PMH; Mysona DP; Purohit SB; Myers E; Lee WS; Dun B; Xu D; Liu H; Hopkins D; Nechtman J; Scelsi CL; Mittal PK; Kleven D; Wallbillich JJ; Rungruang B; Ghamande S; She JX
    Gynecol Oncol; 2020 May; 157(2):340-347. PubMed ID: 32067813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma.
    Zhang L; Zhu P; Tong Y; Wang Y; Ma H; Xia X; Zhou Y; Zhang X; Gao F; Shu P
    Onco Targets Ther; 2019; 12():7005-7014. PubMed ID: 31695415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    Dong F; Davineni PK; Howitt BE; Beck AH
    Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.
    Hinchcliff E; Paquette C; Roszik J; Kelting S; Stoler MH; Mok SC; Yeung TL; Zhang Q; Yates M; Peng W; Hwu P; Jazaeri A
    Cancer Immunol Immunother; 2019 Sep; 68(9):1515-1526. PubMed ID: 31515669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
    Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
    Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
    Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
    JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma.
    Liu G; Chen L; Ren H; Liu F; Dong C; Wu A; Liu Z; Zheng Y; Cheng X; Liu L
    Int J Biol Sci; 2018; 14(14):2012-2022. PubMed ID: 30585265
    [No Abstract]   [Full Text] [Related]  

  • 19. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
    Hew KE; Miller PC; El-Ashry D; Sun J; Besser AH; Ince TA; Gu M; Wei Z; Zhang G; Brafford P; Gao W; Lu Y; Mills GB; Slingerland JM; Simpkins F
    Clin Cancer Res; 2016 Feb; 22(4):935-47. PubMed ID: 26482043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients.
    Niu Y; Sun W; Chen K; Fu Z; Chen Y; Zhu J; Chen H; Shi Y; Zhang H; Wang L; Shen HM; Xia D; Wu Y
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2106-2114. PubMed ID: 31533939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.